-
A Phase 1/2a Multicenter Open-Label Non-Randomized First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors.
You can participate in this study If you are diagnosed with HER2-positive or HER2-expressing advanced/unresectable, recurrent tumor that is refractory to or intolerable with ...Phase
Interventional
